A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

NCT06277024 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Overall Response Rate

Interventions

DRUG: Combination of Cardonizumab with Lenvatinib and SOX regimen

Sponsor

Fujian Medical University